A LinkedIn post from Tobin Scientific highlights Enterprise Account Executive Steve Yankanich, emphasizing his 30 years in sales and five years in life sciences logistics with a focus on biorepository storage and infrastructure strategy. The post underscores his experience in managing complex conversations around cold storage, laboratory relocations, and GMP environments, and his role in guiding clients toward redundancy planning for critical materials.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content suggests Tobin Scientific is prioritizing consultative expertise in off-site storage and cold chain strategy, positioning the company as a partner in risk reduction rather than a commodity logistics provider. For investors, this emphasis on high-touch, specialized advisory capabilities may support pricing power, deepen customer relationships in biotech and clinical research, and potentially enhance recurring revenue linked to long-term storage and risk-mitigation solutions.
By framing biorepository and cold chain services as integral to protecting irreplaceable research and patient-related outcomes, the post aligns Tobin Scientific with mission-critical operations in the life sciences value chain. This positioning could help differentiate the firm in a competitive logistics market, support customer retention, and create opportunities to capture share in higher-margin segments where failure tolerance is minimal.

